Hormone therapy and thromboembolic disease.

Area of Science:

• Reproductive endocrinology
• Thrombosis research
• Pharmacovigilance

Background:

• Hormone therapy is associated with an increased risk of venous thromboembolism (VTE).
• Modifications in hormone therapy formulations and administration routes have aimed to mitigate this risk.
• Understanding the evolving VTE risk profiles of different hormone therapies is critical for patient safety.

Purpose of the Study:

• To review current evidence on the VTE risk associated with various hormone therapies.
• To summarize recent findings regarding newer hormone therapy formulations and administration routes.
• To provide an update on factors influencing VTE risk in hormone therapy users.

Main Methods:

• Systematic review of existing literature on hormone therapy and VTE.
• Analysis of data comparing different generations of progestagens and estrogen dosages.
• Evaluation of evidence on transdermal versus oral administration and the impact of inherited thrombophilia.

Main Results:

• Third-generation progestagen contraceptives show a higher VTE risk than second-generation ones.
• Hormone replacement therapy increases VTE risk 2-3 fold; transdermal routes may be less thrombogenic than oral.
• VTE risk is amplified in individuals with inherited thrombophilia, with higher absolute risk in postmenopausal women.

Conclusions:

• Individual risk factor assessment is essential before initiating hormone therapy.
• Further research is needed to determine the comparative safety of newer hormone therapy compounds regarding thrombosis risk.